罗欣药业(002793) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 1,742,344,087.59, representing a 36.62% increase compared to CNY 1,275,320,618.09 in the same period last year[7] - Net profit attributable to shareholders was CNY 157,400,135.37, up 41.02% from CNY 111,611,818.85 year-on-year[7] - The net profit after deducting non-recurring gains and losses was CNY 150,831,187.15, reflecting a 52.50% increase from CNY 98,907,054.75 in the previous year[7] - The basic earnings per share increased to CNY 0.11, a rise of 37.50% from CNY 0.08 in the same quarter last year[7] - The diluted earnings per share rose to CNY 0.10, marking a 42.86% increase from CNY 0.07 year-on-year[7] - The total operating profit for the first quarter of 2021 was approximately CNY 186.29 million, an increase from CNY 133.44 million in the same period last year, representing a growth of 39.5%[40] - The total comprehensive income for the first quarter was CNY 161.38 million, compared to CNY 114.99 million in the same period last year, indicating a rise of 40.2%[41] - The total profit for the first quarter was CNY 187.69 million, compared to CNY 133.17 million in the same period last year, reflecting a growth of 40.8%[40] Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,970,518,166.76, a 3.22% increase from CNY 7,721,699,746.56 at the end of the previous year[7] - The net assets attributable to shareholders increased to CNY 4,205,368,327.96, up 4.08% from CNY 4,040,506,447.75 at the end of the last year[7] - Total liabilities increased to CNY 3,452,052,980.96 from CNY 3,371,340,862.68[33] - The total assets of the company as of March 31, 2021, amounted to approximately ¥7.97 billion, an increase from ¥7.72 billion at the end of 2020[31] - The total equity attributable to shareholders reached CNY 4,040,506,447.75, while total equity was CNY 4,350,358,883.88[56] - Long-term borrowings rose significantly by 115.34% to ¥653.17 million as of March 31, 2021, compared to ¥303.33 million at the end of 2020, indicating new financing activities[18] - The company’s total liabilities increased, with short-term borrowings reported at 837,403,586.20 CNY, consistent with previous levels[55] Cash Flow - The net cash flow from operating activities was negative at CNY -248,079,595.26, a decline of 44.17% compared to CNY -172,069,444.30 in the same period last year[7] - Cash inflows from operating activities amounted to CNY 1.70 billion, an increase from CNY 1.44 billion year-on-year, representing a growth of 18.4%[47] - The net cash flow from investment activities was -91,835,373.79 CNY, contrasting with a positive 411,324,713.62 CNY in the prior year[48] - Cash inflow from financing activities totaled 893,724,888.38 CNY, compared to 572,000,000.00 CNY previously, reflecting an increase in financing efforts[49] - The ending balance of cash and cash equivalents was 920,721,238.11 CNY, down from 1,223,703,360.29 CNY year-over-year[49] Expenses - Sales expenses increased by 66.10% to ¥642.22 million in Q1 2021 from ¥386.65 million in Q1 2020, reflecting a recovery in promotional activities[18] - Total operating costs for Q1 2021 amounted to CNY 1,550,245,400.86, up from CNY 1,173,792,477.37 in the previous period[39] - Research and development expenses decreased to CNY 64,829,504.01 from CNY 96,748,171.03 year-over-year[39] - The company’s management expenses increased to CNY 12.37 million from CNY 7.05 million, representing a rise of 75.0%[43] Shareholder Information - The company reported a total of 19,794 common shareholders at the end of the reporting period[10] - The company has committed to not transferring shares for 36 months following significant asset restructuring and share issuance[14] - The company reported no significant non-operating fund occupation by controlling shareholders during the reporting period[25] Other Information - The company has not undergone an audit for the first quarter report, indicating that the figures are unaudited[60] - The company has a capital reserve of CNY 204,937,847.37, reflecting its financial stability[56] - The company’s retained earnings were reported at CNY 2,440,240,798.86, showcasing its ability to reinvest profits[56] - The company reported other income of CNY 2.82 million, up from CNY 0.86 million in the previous year, showing a significant increase of 228.5%[40]